Rescheduling Hydrocodone Combination Products Will Lead to More Responsible Use

Published Online: Monday, January 27, 2014
Follow Pharmacy_Times:
In this video, Mary Lynn McPherson, PharmD, professor and vice chair at the University of Maryland School of Pharmacy, argues that rescheduling hydrocodone combination products as Schedule II drugs will introduce limitations that will lead to more responsible prescribing of the drugs and monitoring of their use.
 
This is the ninth in a series of videos in which Dr. McPherson argues in favor of categorizing hydrocodone combination products as Schedule II drugs, and Jeff Fudin, PharmD, argues against doing so. (Drs. McPherson and Fudin were assigned to take these positions for a session at the American Society of Health-System Pharmacists 2013 Midyear Clinical Meeting in Orlando, and their arguments do not necessarily reflect their personal positions on the issue.)
 
These videos were filmed at the ASHP 2013 Midyear Clinical Meeting in Orlando.

Related Articles
Drug addiction is one thing, but diverting that poison onto the streets when pharmacists are told in no uncertain terms not to do so isn’t looked upon so forgivingly.
While extended-release opioid analgesics are an essential component of pain management, abuse and misuse of these medications can cause substantial morbidity and mortality.
With so many NAPLEX review books on the market, how can you decide which one is best?
The rate of deaths from opiate medications in the United States has increased 4-fold over the past decade.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$